Tag Archives: Johnson’s

Earnings bulletin: Johnson & Johnson’s second quarter of 2019

Johnson & Johnson kicked off the second-quarter earnings season Tuesday, reporting that its pharma unit outperformed struggling consumer healthcare and medical device segments. Pharma posted sales growth of 1.7% and operational growth of 4.4% to hit $ 10.53 billion in sales. Across J&J’s entire business, the company’s revenue sank 1.3% to $ 20.56 billion. At… Read More »

Expert witness: Johnson & Johnson’s role in opioid crisis may be ‘worse’ than Purdue’s

Dr. Andrew Kolodny, the co-director of the Opioid Policy Research Collaborative at Brandeis University, made the comments during the 11th day of the historic trial in Oklahoma that is aimed at holding Johnson & Johnson and its subsidiaries responsible for the state’s opioid epidemic. “Until I had an opportunity to review discovery documents,” Kolodny testified,… Read More »